Welby Inc offers patients and to their family a digital tools helping medical treatment and prevention of progression of disease. The company co-develops and co-provides digital services with pharmaceuticals, medical device companies, governments along with patients and health care professionals.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Welby has a last 12-month revenue of $3.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Welby achieved revenue of $3.5M and an EBITDA of -$5.3M.
Welby expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Welby valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $3.8M | $3.5M | XXX | XXX | XXX |
Gross Profit | $5.0M | $2.5M | XXX | XXX | XXX |
Gross Margin | 131% | 71% | XXX | XXX | XXX |
EBITDA | -$3.3M | -$5.3M | XXX | XXX | XXX |
EBITDA Margin | -87% | -150% | XXX | XXX | XXX |
Net Profit | $0.2M | -$3.4M | XXX | XXX | XXX |
Net Margin | 6% | -96% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Welby's stock price is JPY 306 (or $2).
Welby has current market cap of JPY 2.5B (or $16.8M), and EV of JPY 2.0B (or $13.2M).
See Welby trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$13.2M | $16.8M | XXX | XXX | XXX | XXX | $-0.66 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Welby has market cap of $16.8M and EV of $13.2M.
Welby's trades at 3.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Welby's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Welby and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $13.2M | XXX | XXX | XXX |
EV/Revenue | 3.8x | XXX | XXX | XXX |
EV/EBITDA | -2.5x | XXX | XXX | XXX |
P/E | -3.1x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpWelby's NTM/LTM revenue growth is -100%
Welby's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Welby's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Welby's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Welby and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -8% | XXX | XXX | XXX | XXX |
EBITDA Margin | -150% | XXX | XXX | XXX | XXX |
EBITDA Growth | 59% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 196% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
MedAdvisor | XXX | XXX | XXX | XXX | XXX | XXX |
Oneview Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
Life Semantics | XXX | XXX | XXX | XXX | XXX | XXX |
Kooth | XXX | XXX | XXX | XXX | XXX | XXX |
Alignment Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Welby acquired XXX companies to date.
Last acquisition by Welby was XXXXXXXX, XXXXX XXXXX XXXXXX . Welby acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Welby founded? | Welby was founded in 2011. |
Where is Welby headquartered? | Welby is headquartered in Japan. |
How many employees does Welby have? | As of today, Welby has 33 employees. |
Is Welby publicy listed? | Yes, Welby is a public company listed on TKS. |
What is the stock symbol of Welby? | Welby trades under 4438 ticker. |
When did Welby go public? | Welby went public in 2019. |
Who are competitors of Welby? | Similar companies to Welby include e.g. MedAdvisor, Oneview Healthcare, Life Semantics, Kooth. |
What is the current market cap of Welby? | Welby's current market cap is $16.8M |
What is the current revenue of Welby? | Welby's last 12-month revenue is $3.5M. |
What is the current EV/Revenue multiple of Welby? | Current revenue multiple of Welby is 3.8x. |
What is the current revenue growth of Welby? | Welby revenue growth between 2023 and 2024 was -8%. |
Is Welby profitable? | Yes, Welby is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.